Aurinia Pharmaceuticals (NASDAQ:AUPH) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) issued its earnings results on Friday. The biotechnology company reported $0.23 earnings per share for the quarter, topping the consensus estimate of $0.22 by $0.01, FiscalAI reports. Aurinia Pharmaceuticals had a return on equity of 26.11% and a net margin of 100.84%. The business had revenue of $83.70 million for the quarter, compared to analysts’ expectations of $83.61 million.

Aurinia Pharmaceuticals Trading Down 3.0%

AUPH traded down $0.52 during trading on Friday, hitting $16.69. The company’s stock had a trading volume of 477,576 shares, compared to its average volume of 1,146,767. The firm’s 50 day moving average price is $16.50 and its 200-day moving average price is $15.64. Aurinia Pharmaceuticals has a twelve month low of $12.07 and a twelve month high of $19.25. The stock has a market cap of $2.22 billion, a PE ratio of 7.28 and a beta of 1.60. The company has a debt-to-equity ratio of 0.07, a current ratio of 5.42 and a quick ratio of 4.97.

Wall Street Analyst Weigh In

AUPH has been the topic of a number of analyst reports. TD Cowen lifted their target price on shares of Aurinia Pharmaceuticals from $17.00 to $18.00 and gave the stock a “buy” rating in a research note on Wednesday, October 21st. Zacks Research lowered Aurinia Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 21st. Bloom Burton upgraded Aurinia Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 20th. Royal Bank Of Canada increased their target price on shares of Aurinia Pharmaceuticals from $15.00 to $16.00 and gave the company a “sector perform” rating in a research report on Friday, August 7th. Finally, Weiss Ratings raised shares of Aurinia Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a report on Thursday, October 22nd. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, Aurinia Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $17.75.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s principal product is Lupkynis (voclosporin), an oral calcineurin inhibitor used in combination with other immunosuppressive therapies to treat adults with active lupus nephritis, a serious kidney complication of systemic lupus erythematosus.

Voclosporin was approved by the U.S. Food and Drug Administration in 2021, making Lupkynis the first oral therapy specifically approved in the United States for adult patients with active lupus nephritis.